結腸直腸癌：針對個別化醫療之成長動向 是由出版商Datamonitor在2009年10月所出版的。
這份英文市場調查報告書包含96 pages 價格從美金11400起跳。
結腸直腸癌在現今7個主要市場裡預計至2018年止將會超越49萬件。目前有77種藥劑正在開發，預估2018年為止銷售會達到13億9,800美元。
本報告為結腸癌治療用之第3相後補藥品概略、2018年為止世界主要7個市場之銷售預測、今後市場機會與尚未滿足之需求來做整理，並以下列摘要形式闡述。
摘要
實施概要
第1章 產品線摘要與動向
- 主要調查結果
- 產品線摘要
- 主要參與結腸直腸癌產品線之企業
- 研究開發相關之企業戰略
第2章 結腸直腸癌：市場的潛在性
- 主要調查結果
- 定義
- 流行病學
- 現今的治療法
- 現今的比較治療法
- 針對結腸直腸癌相關尚未滿足之需求
第3章 研究開發方式
第4章 產品線分析與預測：分子標靶療法
- 主要調查結果
- 分子標靶療法之摘要
- Aflibercept
- Brivanib
- Recentin
- MK-0646
革新之早期方式
- 主要調查結果
- 革新之早期方式之摘要
- 結腸直腸癌未來之治療法
參考資料
附錄
Abstract
Introduction
CRC incidence will be over 490,000 cases by 2018 in the seven major markets.
This large patient base will translate into a high commercial potential for
the development of novel, more effective therapies. Currently, there are 77
agents in development for CRC, 4 of which are in late-phase development.
Collectively, they are forecast to achieve sales of $1,398m by 2018.
Scope of this research
- Examination of the CRC pipeline with in-depth clinical and commercial
profiles of Phase III candidates
- Seven major pharmaceutical market sales forecasts for Phase III pipeline
products through to 2018
- Segmentation and analysis of the current CRC pipeline by developmental
phase, drug class and company
- Insight and analysis of market potential including commercial opportunity,
epidemiology and discussion of unmet needs
Research and analysis highlights
The CRC pipeline consists of 77 drugs, of which 60% are molecular targeted
therapies (MTTs), 22% are immunotherapies, and 17% are cytotoxic therapies.
MTTs constitute the bulk of the CRC pipeline. This is in line with R&D in
other tumor types, where there is a shift away from standard cytotoxic
therapies towards MTTs and personalized medicine.
The late-phase CRC pipeline consists only of MTTs. Except for one agent; all
the others are being investigated in previously-treated patients. Drug
developers appear to be pursuing approval for treatment in the second-line
setting where barriers to market entry are lower and the high level of unmet
need may facilitate a drug' s uptake and approval.
Aflibercept (VEGF-Trap; Regeneron/Sanofi-Aventis) is forecast to achieve the
highest level of sales among the late-phase pipeline candidates in the CRC
market, generating £604m by 2018 in the seven major pharmaceutical
markets.
Key reasons to purchase this research
- Identify key drugs and companies within the CRC pipeline based on sales
forecasts to 2018 and Datamonitor drug assessment.
- Characterize unmet need and poorly served patient subsets within the CRC
market and assess the potential for pipeline products to fulfil them.
- Segmentation and analysis of the current CRC pipeline by developmental
phase, drug class, company and indication.
Table of Contents
OVERVIEW
EXECUTIVE SUMMARY
- Strategic scoping and focus
- Datamonitor insight into the colorectal cancer market
- Datamonitor pipeline assessment summary
- Related reports
- Upcoming related reports
1. PIPELINE OVERVIEW AND DYNAMICS
- Key findings
- Pipeline overview
- Pipeline summary
- Comparative forecasts
- Datamonitor pipeline assessment summary
- Key companies involved in the colorectal cancer (CRC) pipeline
- Key R&D company strategies
- Ongoing shift towards molecular targeted therapies in colorectal cancer
- Line extensions of already marketed drugs
2. COLORECTAL CANCER - MARKET POTENTIAL
- Key findings
- Definition
- Introduction
- Histology
- Risk factors
- Symptoms
- Screening and diagnosis
- Patient segmentation
- Epidemiology
- Seven major markets
- Rest of the world
- Current treatment options
- Surgery remains the primary treatment choice for early-stage CRC
- Adjuvant therapy extends disease-free survival in Stage III patients
- Combination chemotherapy is the standard of care in metastatic disease
- Current comparator therapy
- Eloxatin (oxaliplatin; Sanofi-aventis)
- Unmet need in colorectal cancer (CRC)
- Better screening approaches needed to decrease mortality rates
- There is a need for more effective therapies in both early-stage and
advanced disease
- Biomarkers and the selection of patients may help improve outcomes
- Target product profile versus current level of attainment
3. R&D APPROACH
- Key findings
- Clinical trial design in colorectal cancer (CRC)
- Patient selection
- Clinical trial endpoints in oncology
4. PIPELINE ANALYSIS & FORECASTS: MOLECULAR TARGETED THERAPIES
- Key findings
- Overview of the molecular targeted therapies
- Pipeline summary
- Comparative forecasts
- Aflibercept (VEGF-Trap; Regeneron/Sanofi-aventis)
- Drug overview
- Drug profile
- Key historical events
- SWOT analysis
- Clinical trial data
- Clinical attractiveness
- Commercial attractiveness
- Datamonitor drug assessment summary
- Satisfaction of unmet needs
- Forecasts to 2018
- Brivanib (Bristol-Myers Squibb)
- Drug overview
- Drug profile
- Key historical events
- SWOT analysis
- Clinical trial data
- Clinical attractiveness
- Commercial attractiveness
- Datamonitor drug assessment summary
- Satisfaction of unmet needs
- Forecasts to 2018
- Recentin (cediranib; AstraZeneca)
- Drug overview
- Drug profile
- Key historical events
- SWOT analysis
- Clinical trial data
- Clinical attractiveness
- Commercial attractiveness
- Datamonitor drug assessment summary
- Satisfaction of unmet needs
- Forecasts to 2018
- MK-0646 (Merck/Pierre Fabre)
- Drug overview
- Drug profile
- Key historical events
- SWOT analysis
- Clinical trial data
- Commercial attractiveness
- Datamonitor drug assessment summary
- Satisfaction of unmet needs
- Forecasts to 2018
5. INNOVATIVE EARLY-STAGE APPROACHES
- Key findings
- Overview of early-stage innovative projects
- TRAIL
- Insulin-like growth factor receptor (IGFR)
- MAP kinase pathway
- The future of treatment of colorectal cancer (CRC)
- Molecular markers will become an important part of therapy for patient
selection
- The future will see more combination therapies to target multiple
pathways
- Increased understanding of cancer evolution should result in a large
range of potential drug targets
BIBLIOGRAPHY
- Journals
- Websites
- Datamonitor reports
APPENDIX
- Methodology
- Epidemiology forecasts
- Product forecasts
- Datamonitor drug assessment scorecard
TABLES
- Table: Sales forecasts for late-phase colorectal cancer (CRC) pipeline
products in the seven major markets ($m), 2009 - 2018
- Table: Drugs in late-phase development for colorectal cancer (CRC), 2009
- Table: Sales forecasts for late-stage colorectal cancer (CRC) pipeline
products in the seven major markets ($m), 2009 - 2018
- Table: Amgen' s marketed and pipeline oncology portfolio, 2009
- Table: AstraZeneca' s marketed and pipeline oncology portfolio, 2009
- Table: Roche' s marketed and pipeline oncology portfolio, 2009
- Table: Forecast incidence of colorectal cancer (CRC) in the seven major
pharmaceutical markets, 2009 - 2018
- Table: Molecular targeted therapies (MTTs) approved for use in metastatic
colorectal cancer (CRC), 2009
- Table: Eloxatin (oxaliplatin) - drug profile, 2009
- Table: Ability of Eloxatin to meet unmet needs in the first-line treatment
of metastatic colorectal cancer (CRC), 2009
- Table: Ability of Eloxatin to meet unmet needs in the second-line
treatment of metastatic colorectal cancer (CRC), 2009
- Table: Drugs in late-phase development for colorectal cancer (CRC) , 2009
- Table: Forecast assumptions for molecular targeted therapy colorectal
cancer (CRC) pipeline products across the seven major markets, 2009
- Table: Forecast assumptions for molecular targeted therapy colorectal
cancer (CRC) pipeline products across the seven major markets, 2009
- Table: Sales forecasts for late-phase colorectal cancer (CRC) pipeline
products in the seven major markets ($m), 2009 - 2018
- Table: Aflibercept - drug profile, 2009
- Table: Aflibercept: key historical events
- Table: Clinical development of aflibercept in colorectal cancer (CRC), 2009
- Table: Ability of aflibercept to meet unmet needs in colorectal cancer
(CRC), 2009
- Table: Sales forecast for aflibercept in colorectal cancer (CRC) across
the seven major markets ($m), 2009 - 2018
- Table: Brivanib - drug profile, 2009
- Table: Brivanib: key historical events
- Table: Clinical development of brivanib in colorectal cancer (CRC), 2009
- Table: Phase I results investigating a second-line or higher combination
of Erbitux and brivanib in advanced gastrointestinal malignancies
- Table: Ability of brivanib to meet unmet needs in colorectal cancer (CRC),
2009
- Table: Sales forecast for brivanib in colorectal cancer (CRC) across the
seven major markets($m), 2009 - 2018
- Table: Recentin (cediranib) - drug profile, 2009
- Table: Recentin: key historical events
- Table: Clinical development of Recentin in colorectal cancer (CRC), 2009
- Table: Ability of Recentin to meet unmet needs in colorectal cancer (CRC),
2009
- Table: Sales forecast for Recentin in colorectal cancer (CRC) across the
seven major markets ($m), 2009 - 2018
- Table: MK-0646 - drug profile, 2009
- Table: MK-0646: key historical events
- Table: Clinical development of MK-0646 in colorectal cancer (CRC), 2009
- Table: Ability of MK-0646 to meet unmet needs in colorectal cancer (CRC),
2009
- Table: Sales forecast for MK-0646 in colorectal cancer (CRC) across the
seven major markets, 2009 - 2018 ($m)
- Table: Top 10 early-stage colorectal cancer (CRC) drug targets, 2009
- Table: Datamonitor drug assessment parameters
FIGURES
- Figure: Datamonitor drug assessment summary for molecular targeted
therapies (MTTs) in development for colorectal cancer (CRC), 2009
- Figure: Colorectal cancer (CRC) pipeline split by development phase and
drug class, 2009
- Figure: Datamonitor drug assessment summary for molecular targeted
therapies (MTTs) in development for colorectal cancer (CRC), 2009
- Figure: Incidence and mortality from colorectal cancer (CRC) in the seven
major pharmaceutical markets, 2009 and 2018
- Figure: Incidence of colorectal cancer (CRC) in the rest of the world,
2009 and 2019
- Figure: Datamonitor drug assessment summary for molecular targeted
therapies in development for colorectal cancer (CRC), 2009
- Figure: SWOT analysis for aflibercept, 2009
- Figure: Phase II data on the second-line treatment of aflibercept in
recurrent metastatic colorectal cancer (CRC) patients following failure of
standard therapy
- Figure: Datamonitor drug assessment summary for aflibercept in colorectal
cancer (CRC), 2009
- Figure: Brivanib SWOT analysis, 2009
- Figure: Retrospective analysis evaluating correlation between KRAS status
and efficacy from a Phase I/II study of brivanib in combination with Erbitux
in patients with advanced or metastatic colorectal cancer (CRC)
- Figure: Datamonitor drug assessment summary for brivanib in colorectal
cancer (CRC), 2009
- Figure: SWOT analysis for Recentin, 2009
- Figure: Phase II results for second-line FOLFOX + Recentin versus FOLFOX +
Avastin in metastatic colorectal cancer (CRC) (HORIZON I)
- Figure: Datamonitor drug assessment summary for Recentin in colorectal
cancer (CRC), 2009
- Figure: SWOT analysis for MK-0646, 2009
- Figure: Phase II study of MK-0646 in second-line or higher metastatic
colorectal cancer (CRC) patients with wild-type KRAS
- Figure: Datamonitor drug assessment summary for MK-0646 in colorectal
cancer (CRC), 2009
- Figure: Early-stage colorectal cancer pipeline (CRC) split by drug class,
2009
- Figure: Datamonitor drug assessment summary for molecular targeted
therapies in development for colorectal cancer (CRC), 2009
|
